The SmartPak II monitoring system from Cryoport provides information throughout the logistics process.
The SmartPak II Condition Monitoring System from Cryoport is configured to provide end-to-end visibility on the real-time condition and location of critical biological commodities. The system measures environmental variables and works in with the company’s Cryoportal logistics management platform to monitor commodity conditions and Cryoport Express shipper performance.
The cloud-based Cryoportal retains the critical data analytics generated by the SmartPak II, including chain-of-condition and chain-of-custody. The integration with the logistics management platform enables real-time intervention capabilities. Automated email alerts are sent to stakeholders for any incident of excursion or deviation.
The system tracks the key aspects of each shipment that could affect the quality and/or timing of delivery of the commodity to its intended destination and uses the global positioning system (GPS), cellular technology, and Wi-Fi triangulation, to ensure communication in signal-impaired environments. Variables measured include internal and external temperatures, pressure, humidity, shock, and orientation of the shipper. The system provides Cryoport with the ability to correlate transit-related events to the impact on sample integrity, providing insight on logistics planning and equipment performance.
The Smart Pak II will be fully available on Aug. 31, 2016.
Source: Cryoport, Inc.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.